June 17, 2020 -- A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic cell cancer vaccines.
The collaboration among Saint-Gobain Life Sciences, Kanyr Pharma (a McGill University startup), the Research Institute at the McGill University Health Center, and McGill University's Stem Cell Bioprocessing Laboratory and Plasma Processing Laboratory will develop the vaccine in Saint-Gobain's VueLife "C" Series fluorinated ethylene propylene bags. This single-use option will allow for closed system culture and manufacturing and enable researchers to easily move research-scale bioprocesses to clinical-scale commercial production.
Additionally, Kanyr's Immunyr technology will be incorporated to obtain pharmacologically activated dendritic cells using a proprietary small inhibitor of key phosphatase enzymes. Immunyr was developed to activate each patient's own immune system to target several types of cancer.
Researchers will study protein-surface and cell-surface interactions in realistic bioprocessing conditions to accelerate clinical development. Immunyr will be used to develop several cancer vaccine therapeutic applications and to further demonstrate the value of VueLife bags for cell therapy applications.